| 產品名稱 |
559/64-D 100, 10, 1 [559/64-D] |
| 商品貨號 |
B163787 |
| Organism |
human (B cell); human x mouse (heterohybridoma) |
| Tissue |
peripheral blood; mononuclear cells |
| Cell Type |
hybridoma:lymphoblast B lymphocyte; Epstein-Barr virus (EBV) transforme |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
2 Cells contain Human Immunodeficiency Virus Type 1 (HIV-1)
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Age |
adult |
| Strain |
Strain: BALB/c (myeloma) |
| Applications |
It has broad HIV group specificity and reacts with the HTLV-IIIB, MN and SF-2 strains of HIV-1. The antibody is specific for the CD4-binding domain of the gp120 protein of HIV-1; it inhibits CD4-rgp120 binding. The antibody can be used in ELISA and neutralization assays. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Antibody producing clones were expanded and fused with SHM-D33 heterohybridoma cells (ATCC CRL-1668). |
| Clinical Data |
Human peripheral blood mononuclear cells from HIV seropositive patients were transformed with Epstein-Barr virus (EBV). |
| Comments |
Human peripheral blood mononuclear cells from HIV seropositive patients were transformed with Epstein-Barr virus (EBV). Antibody producing clones were expanded and fused with SHM-D33 heterohybridoma cells (ATCC CRL-1668). The antibody is specific for the CD4-binding domain of the gp120 protein of HIV-1; it inhibits CD4-rgp120 binding. It has broad HIV group specificity and reacts with the HTLV-IIIB, MN and SF-2 strains of HIV-1. The antibody can be used in ELISA and neutralization assays. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 2 X 10 exp6 viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1 kappa |
| Name of Depositor |
New York University |
| Deposited As |
human (B cell); human x mouse (heterohybridoma) |
| References |
Zolla-Pazner S, et al. Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV. US Patent 6,241,986 dated Jun 5 2001
Wang H, et al. Human monoclonal and polyclonal anti-human immunodeficiency virus-1 antibodies share a common clonotypic specificity. Eur. J. Immunol. 22: 1749-1755, 1992. PubMed: 1378015
|
